metricas
covid
Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) Standardized uptake value and metabolic tumor volume measured by 18F FDG PET/CT ...
Journal Information
Vol. 33. Issue 5.
Pages 268-273 (September - October 2014)
Share
Download PDF
More article options
Visits
441
Vol. 33. Issue 5.
Pages 268-273 (September - October 2014)
Original
Standardized uptake value and metabolic tumor volume measured by 18F FDG PET/CT are sensitive biomarkers for the presence of lymph node metastasis in patients with cervical carcinoma
El valor de captación estándar y el volumen metabólico tumoral medidos mediante 18F FDG PET/TC constituyen biomarcadores sensibles a la presencia de metástasis de ganglios linfáticos en pacientes con carcinoma cervical
Visits
441
G.U. Vural
Corresponding author
drgulin@yahoo.com

Corresponding author.
, B.E. Akkas, B.B. Demirel
Department of Nuclear Medicine, Ankara Oncology Education and Research Hospital, Ankara, Turkey
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (3)
Show moreShow less
Tables (2)
Table 1. Patient characteristics.
Tables
Table 2. Association of clinical FIGO stage with patient and tumor characteristics.
Tables
Show moreShow less
Abstract

The aim of this study was to evaluate whether tumor standardized uptake value (SUVmax) and metabolic tumor volume (MTV) associate with the presence of PET-positive pelvic/para-aortic lymph nodes (LN) in cervical cancer patients.

Method

Seventy-four patients with stage IB-IVB cervical cancer (squamous [n:66], nonsquamous [n:8]), who were referred to FDG-PET/CT department for initial staging, were enrolled in this study.

Results

Patients were staged according to International Federation of Gynecology and Obstetrics [FIGO] criteria as; stage I (n:5), stage II (n:25), stage III (n:15) and stage IV (n:29). PET/CT detected 53 patients with hypermetabolic LN (average SUVmax: 7.5±4.1, range: 4.1–22.8, pelvic LN: 29 patients, para-aortic LN:5 patients, pelvic and para-aortic LN:19 patients). SUVmax and MTV were significantly higher in patients with PET-positive LN compared to others (18.4 and 88.8cm3 vs. 13.9 and 39.9cm3 respectively, p=0.007 for SUVmax, p=0.0001 for MTV). Cut-off values in association with PET-positive LN were 15.2 for SUVmax and 35cm3 for MTV on ROC curve analysis. There was no correlation between SUVmax and MTV (correlation coefficient (R2)=0.07). MTV differed significantly with FIGO stages (41, 98 and 107cm3, in stage II, III and IV respectively, p=0.015).

Conclusion

Presence of PET-positive LN correlates with tumor SUVmax and MTV of cervical tumor. These findings support the use of PET/CT in the pretreatment evaluation of cervical cancer patients in order to identify cases with high risk of lymphatic involvement.

Keywords:
Cervical cancer
FDG
PET/CT
Lymphatic involvement
SUVmax
Metabolic tumor volume
Resumen

El objetivo de este estudio fue el de evaluar si el valor de captación tumoral estándar (SUVmax) y el volumen tumoral metabólico (VTM) se asocian a la presencia de ganglios linfáticos pélvicos/para-aórticos PET-positivos en los pacientes de cáncer cervical.

Método

Se incluyó en este estudio a setenta y cuatro pacientes con cáncer cervical en estadio IB-IVB (escamoso [n:66], no escamoso [n:8]), que fueron remitidos a la unidad de FDG-PET/TC para una estadificación inicial.

Resultados

Se clasificó a los pacientes de acuerdo a los criterios de la Federación Internacional de Ginecología y Obstetricia [FIGO], es decir; estadio I (n:5), estadio II (n:25), estadio III (n:15) y estadio IV (n:29). La exploración PET/CT detectó 53 pacientes con ganglios hipermetabólicos (SUVmax medio: 7,5±4,1, rango: 4,1-22,8, ganglios pélvicos: 29 pacientes, ganglios para-aórticos: 5 pacientes, ganglios pélvicos y para-aórticos: 19 pacientes). Los valores de SUVmax y VTM fueron considerablemente superiores en pacientes con ganglios PET-positivos en comparación al resto (18,4 y 88,8cm3 frente a 13,9 y 39,9cm3 respectivamente, p=0,007 para SUVmax, p=0,0001 para VTM). Los valores límite en cuanto a ganglios PET-positivos fueron de 15,2 para SUVmax y 35cm3 para VTM en un análisis de curva ROC. No se produjo correlación entre SUVmax y MTV (coeficiente de correlación: (R2)=0.07). El VTM difirió significativamente de los estadios FIGO (41, 98 y 107cm3, en los estadios II, III y IV respectivamente, p=0,015).

Conclusión

La presencia de ganglios PET-positivos guarda correlación con el SUVmax tumoral y el VTM del tumor cervical. Estos hallazgos apoyan el uso de PET/TC en la evaluación previa al tratamiento de los pacientes de cáncer cervical, a fin de identificar los casos con elevado riesgo de implicación linfática.

Palabras clave:
Cáncer cervical
FDG
PET/TC
Implicación linfática
SUVmax
Volumen tumoral metabólico

Article

These are the options to access the full texts of the publication Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
Member
If you are a member of the Spanish Society of Nuclear Medicine and Molecular Imaging (SEMNIM), you can access the full text of the contents of the Revista Española de Medicina Nuclear e Imagen Molecular through the journal links published on the SEMNIM website (link: http://socios.semnim.es/?ir-a=remnim), after logging in as a member.

If you experience access problems, you can contact the SEMNIM Technical Secretariat by email at secretaria.tecnica@semnim.es or by phone at +34 619 594 780.
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools